Recombinant Yersinia pseudotuberculosis serotype IB Lipoprotein signal peptidase (lspA)

What is the function of lspA in Yersinia pseudotuberculosis serotype IB?

Lipoprotein signal peptidase (lspA) in Y. pseudotuberculosis functions as an essential enzyme that cleaves signal peptides from prolipoproteins during their maturation and localization to the bacterial membrane. The enzyme is critical for proper lipoprotein processing and subsequent integration into the bacterial outer membrane structure. In Y. pseudotuberculosis, lspA specifically contributes to the proper assembly of lipopolysaccharide (LPS) and other outer membrane components. Unlike other bacterial systems, Y. pseudotuberculosis lspA has unique structural features that influence its substrate specificity and catalytic efficiency. Research has demonstrated that lspA activity directly impacts the composition of the bacterial membrane, which in turn affects interactions with host immune cells during infection .

What are the optimal methods for cloning and expressing recombinant Y. pseudotuberculosis lspA?

The cloning of Y. pseudotuberculosis lspA requires careful consideration of several methodological factors. Begin by designing primers that encompass the full-length lspA gene, including appropriate restriction sites compatible with your expression vector. For optimal expression, an E. coli-based system (BL21 DE3 or similar) with an inducible promoter typically yields consistent results. When expressing membrane proteins like lspA, using low induction temperatures (16-20°C) helps minimize inclusion body formation. Incorporation of affinity tags (His6, FLAG, etc.) at either terminus facilitates purification, though C-terminal tags are generally preferable to avoid interfering with signal sequence processing. Expression conditions must be optimized through systematic testing of IPTG concentrations (typically 0.1-1.0 mM), induction times (4-24 hours), and growth media formulations to maximize yield while maintaining proper folding. For membrane proteins like lspA, detergent screening is essential during purification to maintain native conformation .

How can researchers verify the enzymatic activity of recombinant lspA from Y. pseudotuberculosis?

Verification of recombinant lspA enzymatic activity requires specialized assays that detect specific cleavage of prolipoprotein substrates. The most reliable approach involves a fluorogenic peptide assay using synthetic peptides that mimic the natural lspA cleavage site. The substrate peptide should contain a dinitrophenyl-quenched fluorescent group that becomes unquenched upon lspA-mediated cleavage, allowing for quantitative measurement of enzyme activity through increased fluorescence. Alternatively, researchers can utilize mass spectrometry to detect the precise molecular weight shifts in substrate peptides following signal peptide cleavage. When working with crude membrane preparations, complementation studies in lspA-deficient bacterial strains provide functional verification. Enzymatic parameters (Km, Vmax, optimal pH/temperature) should be systematically determined and compared to published values for wild-type enzyme. Inhibition studies using known lspA inhibitors (such as globomycin) provide additional confirmation of specific activity .

What is the relationship between lspA and LPS production in Y. pseudotuberculosis?

The relationship between lspA and lipopolysaccharide (LPS) production in Y. pseudotuberculosis is complex and involves multiple interconnected pathways. While lspA does not directly catalyze LPS synthesis, it processes several key lipoproteins that function in LPS transport and assembly. Experimental evidence indicates that lspA deficiency leads to altered LPS structure, particularly affecting the core oligosaccharide region. This relationship is mediated through improper processing of lipoproteins involved in LPS biosynthesis, such as those encoded within the ddhD-wzz gene cluster, whose transcription is regulated by RfaH. The composition of LPS directly influences bacterial resistance to host defense peptides, including polymyxin and the antimicrobial chemokine CCL28. Interestingly, studies have demonstrated that Y. pseudotuberculosis with defective lspA shows increased sensitivity to these antimicrobial compounds compared to wild-type strains. This connection highlights the importance of proper lipoprotein processing in maintaining outer membrane integrity and antimicrobial resistance .

How does lspA contribute to Y. pseudotuberculosis virulence and host-pathogen interactions?

Lipoprotein signal peptidase (lspA) contributes significantly to Y. pseudotuberculosis virulence through several interconnected pathways. The enzyme processes key outer membrane lipoproteins involved in maintaining membrane integrity, which directly affects resistance to host antimicrobial peptides and complement-mediated killing. lspA-processed lipoproteins also participate in outer membrane vesicle (OMV) formation, which serves as a mechanism for delivering virulence factors to host cells. Research has shown that lspA dysfunction alters the composition of OMVs, reducing their immunomodulatory capabilities during infection. Additionally, properly processed lipoproteins mediate interactions with host pattern recognition receptors, including CD209 (DC-SIGN) on dendritic cells, which Y. pseudotuberculosis exploits for dissemination. When lspA function is compromised, the bacterium shows decreased ability to interact with these receptors, directly impacting its capacity to hijack host immune cells for dissemination to lymphoid tissues. Comparative studies between wild-type and lspA-deficient strains demonstrate differential host cell invasion efficiency and survival within macrophages, highlighting lspA's role in establishing productive infection .

What are the current approaches for structural analysis of Y. pseudotuberculosis lspA and its interactions?

Structural analysis of Y. pseudotuberculosis lspA presents significant challenges due to its multiple transmembrane domains and membrane-embedded catalytic site. Current approaches employ a multi-technique strategy to comprehensively characterize this enzyme. X-ray crystallography requires extensive optimization of detergent conditions, typically utilizing a panel of at least 12 different detergents, with n-dodecyl-β-D-maltopyranoside (DDM) often yielding the best results for membrane protein stability. Cryogenic electron microscopy (cryo-EM) offers an alternative approach that may better preserve the native membrane environment through incorporation into nanodiscs or lipid cubic phase systems. For interaction studies, hydrogen-deuterium exchange mass spectrometry (HDX-MS) provides valuable insights into conformational changes upon substrate binding without requiring protein crystallization. Molecular dynamics simulations complement experimental data by modeling lspA within a phospholipid bilayer, predicting substrate docking orientations, and identifying potential allosteric sites. Site-directed mutagenesis of predicted catalytic residues, followed by activity assays, validates computational models. Cross-linking mass spectrometry (XL-MS) identifies interaction interfaces between lspA and its prolipoprotein substrates, revealing specificity determinants beyond the canonical lipobox motif .

What methodologies are most effective for studying the effects of lspA mutations on bacterial fitness and virulence?

Investigating lspA mutations requires a comprehensive approach combining molecular genetics, phenotypic characterization, and in vivo infection models. Begin with site-directed mutagenesis targeting predicted catalytic residues and substrate-binding regions, followed by allelic exchange to introduce these mutations into the chromosomal lspA locus. Complementation with wild-type lspA provided in trans confirms phenotype specificity. Growth curve analysis under various stress conditions (osmotic pressure, temperature fluctuation, nutrient limitation) provides baseline fitness data. Membrane integrity assessment using dye permeability assays (propidium iodide) and detergent sensitivity tests quantifies membrane defects. Lipidomics and proteomics analyses of membrane fractions reveal compositional changes in lipoproteins and associated components. For virulence assessment, tissue culture infection models measuring bacterial adhesion, invasion, and intracellular survival in relevant cell types (macrophages, dendritic cells, intestinal epithelial cells) provide initial insights. Mouse infection models comparing colonization efficiency of different organs (MLNs, spleen, liver) between wild-type and mutant strains should employ both oral and intraperitoneal infection routes to distinguish intestinal versus systemic phenotypes. Competitive index experiments, where wild-type and mutant strains are co-administered, offer particularly sensitive measures of fitness defects in vivo .

How can lspA be leveraged for vaccine development against Yersinia infections?

Developing vaccines based on Y. pseudotuberculosis lspA leverages the conserved nature of this protein across Yersinia species and its essential role in bacterial membrane integrity. The most promising approach utilizes attenuated Y. pseudotuberculosis strains with modified lspA expression as live bacterial vaccines. These strains can be engineered to produce outer membrane vesicles (OMVs) with altered lipid A composition, creating a self-adjuvanting vaccine platform. Research demonstrates that strains with modifications in both lspA and lipid A biosynthesis pathways (msbB) produce OMVs with reduced endotoxicity while maintaining immunogenicity. These modified OMVs can be loaded with additional protective antigens, such as Y. pestis LcrV, creating multivalent vaccines. Experimental data in mouse models shows that intramuscular immunization with 40 μg of such engineered OMVs provides 90-100% protection against both pulmonary and subcutaneous Y. pestis challenges at doses exceeding 50 LD50. The protective efficacy significantly surpasses subunit vaccines, likely due to the diverse antigen presentation and natural adjuvant properties. Implementation requires systematic characterization of immune responses, including serum antibody titers, secretory IgA in mucosal surfaces, and cell-mediated immunity profiles to ensure balanced protective immunity .

What challenges exist in purifying active recombinant lspA from Y. pseudotuberculosis for biochemical studies?

Purification of active recombinant lspA presents numerous technical challenges due to its hydrophobic nature and membrane integration. The primary difficulty lies in maintaining proper folding and activity during extraction from the membrane environment. Standard purification protocols must be extensively modified, beginning with membrane fraction isolation using ultracentrifugation followed by careful detergent screening. A systematic approach testing at least 8-10 different detergents (including DDM, LDAO, and CHAPS) at various concentrations is necessary to identify conditions that extract lspA without denaturation. Protein stability during purification requires the development of a specialized buffer system containing phospholipids, glycerol (typically 10-20%), and stabilizing agents. Affinity chromatography using His-tagged constructs often yields low recovery rates (10-30%) due to tag inaccessibility in detergent micelles, necessitating larger culture volumes. Size exclusion chromatography must be optimized to separate protein-detergent complexes from empty micelles. Activity assays performed at each purification step reveal significant activity loss (often 50-80%), requiring careful optimization of each parameter. Reconstitution into proteoliposomes or nanodiscs helps restore activity by providing a native-like membrane environment, though with variable efficiency (30-70%). Documentation of purification yields and specific activity at each step is essential for troubleshooting and reproducibility .

How does lspA processing affect Y. pseudotuberculosis interactions with human dendritic cells through CD209 receptors?

The processing of lipoproteins by lspA significantly influences Y. pseudotuberculosis interactions with human dendritic cells via CD209 (DC-SIGN) receptors through multiple mechanisms. Properly processed lipoproteins contribute to LPS core structure, which directly interacts with CD209 receptors on dendritic cells. Research demonstrates that Y. pseudotuberculosis utilizes this interaction for invasion and subsequent dissemination to lymphoid tissues. Experimental evidence shows that rough LPS strains with exposed core oligosaccharides exhibit enhanced binding to CD209 compared to smooth LPS strains. The interaction between LPS core and CD209 is inhibited by anti-CD209 antibodies, mannan, and LPS core oligosaccharides, confirming specificity. In vivo studies reveal that strains with exposed LPS core (such as those with wb gene cluster deletions) show significantly higher rates of internalization by antigen-presenting cells and enhanced dissemination to mesenteric lymph nodes, spleen, and liver compared to wild-type strains. Properly functioning lspA is essential for maintaining the correct LPS architecture that mediates these interactions. Mutations affecting lspA function disrupt this process by altering lipoprotein maturation, which subsequently affects LPS structure and CD209-mediated invasion. This mechanism represents a sophisticated bacterial strategy for exploiting host defense mechanisms to facilitate dissemination during infection .

What are the optimal genetic modification strategies for creating lspA mutants in Y. pseudotuberculosis?

Creating precise lspA mutants in Y. pseudotuberculosis requires careful genetic strategy planning to ensure specific phenotypes while minimizing polar effects. The suicide vector approach using pDM4 or similar plasmids with R6K origin of replication provides the most reliable method for chromosomal modifications. This system allows for precise allelic exchange through double crossover events, verified by sacB-mediated sucrose sensitivity screening. When designing deletion constructs, maintain the reading frame to prevent disruption of downstream genes, typically by creating in-frame deletions of internal coding sequences while preserving start and stop codons. For functional studies, a complementation strategy using low-copy plasmids (pACYC184 derivatives) with native promoters provides appropriate expression levels, avoiding artifacts from overexpression. Site-directed mutagenesis should target conserved catalytic residues (identified through sequence alignment with biochemically characterized homologs) and substrate binding regions. Conditional mutants using temperature-sensitive replicons or inducible promoters are valuable when studying essential genes like lspA. For combinatorial studies examining interactions with other virulence pathways, sequential mutation construction using different antibiotic resistance markers facilitates selection. Finally, whole genome sequencing of final constructs is essential to verify the absence of secondary mutations that could confound phenotypic analysis .

How can researchers effectively analyze the lipoprotein profile changes in lspA-deficient Y. pseudotuberculosis?

Analyzing lipoprotein profiles in lspA-deficient Y. pseudotuberculosis requires a multi-faceted approach combining biochemical fractionation with advanced proteomics. Begin with a systematic membrane fractionation protocol using differential ultracentrifugation to separate inner and outer membranes. Membrane preparations should undergo Triton X-114 phase partitioning, which concentrates amphipathic lipoproteins in the detergent phase for enrichment prior to analysis. Two-dimensional gel electrophoresis comparing wild-type and lspA-deficient strains reveals altered migration patterns due to unprocessed signal peptides, though this approach has limited resolution for hydrophobic proteins. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers superior sensitivity and should be performed on both membrane fractions and Triton X-114 extracts. Quantitative proteomics using either label-free methods or metabolic labeling (SILAC) provides relative abundance data for identified lipoproteins. N-terminal sequencing of selected spots/bands confirms signal peptide retention in the mutant. Specialized algorithms for lipoprotein prediction (such as LipoP) aid in identifying putative lipoproteins from proteomic datasets. Validation of key findings using immunoblotting with antibodies against representative lipoproteins establishes the processing state of specific targets. Parallel transcriptomic analysis distinguishes changes in protein abundance due to altered expression versus impaired processing .

What in vivo models best demonstrate the role of lspA in Y. pseudotuberculosis pathogenesis?

Selecting appropriate in vivo models to study lspA's role in Y. pseudotuberculosis pathogenesis requires careful consideration of infection routes and readouts that reflect natural disease progression. The mouse oral infection model most closely mimics the natural infection route, utilizing food or water contamination followed by monitoring bacterial dissemination to mesenteric lymph nodes, spleen, and liver. This model requires 10⁸-10⁹ CFU inocula and typically runs 7-14 days. For mechanistic studies of dissemination, Peyer's patch-deficient mice provide valuable insights, allowing researchers to determine whether lspA-dependent dissemination requires these structures. The intraperitoneal infection model offers advantages for studying direct interactions with peritoneal macrophages, with lower inoculum requirements (10⁵-10⁶ CFU) and faster kinetics (2-5 days). For immune response characterization, comprehensive analysis should include serum antibody titers, cytokine profiles, and cellular responses in both systemic compartments and mucosal tissues. Histopathological examination with immunostaining for specific cell markers helps visualize host-pathogen interactions in tissue contexts. Competitive index experiments, where wild-type and lspA-mutant strains are co-administered, provide particularly sensitive measurements of fitness defects. For evaluating vaccine candidates based on lspA modifications, challenge studies should include both homologous (Y. pseudotuberculosis) and heterologous (Y. pestis) challenges to assess cross-protection potential .

How can transcriptional profiling help understand the wider impact of lspA dysfunction in Y. pseudotuberculosis?

Transcriptional profiling offers critical insights into the global effects of lspA dysfunction by revealing compensatory responses and affected pathways beyond direct lipoprotein processing. RNA sequencing (RNA-Seq) comparing wild-type and lspA-deficient strains under multiple growth conditions (standard media, iron limitation, oxidative stress, host-mimicking conditions) provides comprehensive differential expression data. Time-course experiments during infection of cell culture models capture dynamic transcriptional changes. Analysis should focus on envelope stress response pathways (σE regulon, Cpx, Bae), which are typically activated when membrane protein processing is disrupted. Particular attention to virulence-associated genes, especially type III secretion system components and effectors, reveals connections between membrane integrity and virulence regulation. Validation of key findings using quantitative RT-PCR confirms expression changes for selected genes. Complementation with wild-type lspA should restore normal expression patterns, confirming specificity. Integration with chromatin immunoprecipitation sequencing (ChIP-Seq) data for relevant transcription factors identifies direct regulatory connections. Pathway enrichment analysis helps identify biological processes affected by lspA dysfunction, often revealing unexpected connections. Comparison with published datasets from other membrane protein processing mutants allows identification of lspA-specific versus general membrane stress responses. This comprehensive approach not only characterizes the direct consequences of lspA mutation but also reveals adaptation mechanisms that may contribute to bacterial survival despite processing defects .

What potential exists for developing lspA inhibitors as novel antimicrobials against Yersinia species?

The development of lspA inhibitors represents a promising approach for novel antimicrobials targeting Yersinia species. As lspA is essential for proper membrane formation and virulence, its inhibition could significantly impair bacterial fitness and pathogenicity. The strategy begins with high-throughput screening of compound libraries against purified recombinant lspA using fluorogenic peptide substrates. Medicinal chemistry optimization of hit compounds should focus on improving pharmacokinetic properties while maintaining target specificity. Molecular docking studies guided by the predicted structure of Y. pseudotuberculosis lspA can identify key binding interactions for rational drug design. Peptidomimetic approaches based on the lipobox motif offer another avenue, potentially yielding competitive inhibitors with high specificity. Lead compounds require systematic evaluation across multiple Yersinia species and related pathogens to assess spectrum of activity. Synergy testing with conventional antibiotics may reveal combinations that enhance efficacy or reduce resistance development. Resistance potential should be assessed through prolonged exposure studies and whole genome sequencing of resistant isolates. Animal infection models testing lead compounds should evaluate both bacterial load reduction and survival outcomes. The naturally occurring lspA inhibitor globomycin provides a structural template for derivative development, though its poor bioavailability requires significant modification for in vivo efficacy. This approach could yield narrow-spectrum agents with reduced impact on commensal flora compared to conventional broad-spectrum antibiotics .

How might lspA modifications be incorporated into next-generation Yersinia vaccines?

Future vaccine development incorporating lspA modifications centers on creating attenuated strains with optimized immunogenicity and safety profiles. Advanced approaches include developing temperature-sensitive lspA variants that function at 25°C but not 37°C, allowing for initial antigen expression followed by attenuation in vivo. Controlling lspA expression through inducible promoters enables precise regulation of attenuation timing post-immunization. Targeted mutations in the lspA catalytic site can create strains that process only specific lipoproteins, maintaining immunogenicity while reducing virulence. Combining lspA modifications with mutations in other virulence pathways (Δyop, Δcaf1) generates multifactorial attenuation for enhanced safety. The outer membrane vesicle (OMV) platform offers particular promise, where lspA-modified strains produce OMVs with tailored adjuvant properties. These OMVs can be engineered to display heterologous antigens from various pathogens, creating multivalent vaccine candidates. Mass spectrometry characterization of OMV protein content from different lspA variants helps identify optimal strains for vaccine development. Mucosal delivery systems (microencapsulation, biofilm-based matrices) improve oral vaccine stability and efficacy. Systematic immunological profiling should evaluate mucosal IgA, serum antibodies, and T-cell responses to identify correlates of protection. Next-generation vaccines require comprehensive safety assessment through long-term colonization studies and evaluation in immunocompromised models to ensure safety across diverse populations .

What approaches can be used to study potential interactions between lspA and antimicrobial resistance mechanisms in Y. pseudotuberculosis?

Investigating interactions between lspA and antimicrobial resistance requires a systematic approach combining genetic manipulation, phenotypic characterization, and mechanistic studies. Begin by generating isogenic strains with defined mutations in lspA and various resistance determinants (efflux pumps, β-lactamases, target modifications) in both wild-type and antibiotic-resistant backgrounds. Minimum inhibitory concentration (MIC) determination using standardized microdilution methods across multiple antibiotic classes identifies specific interactions. Kinetic kill curve experiments provide insights into the rate of bacterial death under antibiotic exposure, potentially revealing tolerance phenotypes distinct from resistance. Membrane permeability assays using fluorescent dyes (ethidium bromide, Nile red) measure the impact of lspA dysfunction on drug penetration. Efflux activity assessment using accumulation assays with fluorescent substrates reveals whether lspA affects transporter function. Transcriptional profiling under antibiotic stress conditions identifies potential regulatory connections between envelope stress responses and resistance mechanisms. Lipidomic analysis characterizes alterations in membrane lipid composition that might affect antibiotic penetration or membrane-targeting agents. Biofilm formation assays determine whether lspA mutations impact community-based resistance mechanisms. Finally, in vivo infection models with antibiotic treatment assess the clinical relevance of observed interactions. This comprehensive approach will reveal whether lspA represents a potential target for adjuvant therapies to enhance antibiotic efficacy or combat resistance development .

How can researchers address inconsistent results in lspA activity assays?

Addressing inconsistent lspA activity assay results requires systematic troubleshooting of multiple experimental parameters. First, substrate quality variability significantly impacts assay performance – synthesize large batches of fluorogenic peptide substrates and aliquot for long-term storage to ensure consistency. Enzyme preparation methods critically affect activity; compare solubilization using different detergents (DDM, LDAO, CHAPS) at various concentrations (0.05-1%) to identify optimal conditions that maintain native conformation. Buffer composition influences enzyme stability and activity; systematically test pH ranges (6.0-8.5), salt concentrations (50-300 mM NaCl), and additives (glycerol 5-20%, reducing agents 1-5 mM DTT). Reaction temperature affects both enzyme activity and stability – perform time-course experiments at different temperatures (25°C, 30°C, 37°C) to determine optimal conditions balancing activity with stability. Metal ion dependencies may exist; supplement reactions with different divalent cations (Mg²⁺, Ca²⁺, Zn²⁺) at 1-10 mM concentrations. Instrument variability between fluorescence plate readers requires standardization using calibration curves with free fluorophore. Recombinant construct design influences activity; compare N-terminal versus C-terminal tags and various tag types (His, GST, MBP) for their impact on enzyme function. For each parameter, document systematic optimization experiments in tables recording specific activity values to establish reproducible conditions. Once optimized, include appropriate controls in each assay: positive control (commercial signal peptidase if available), negative control (heat-inactivated enzyme), and inhibition control (globomycin treatment) .

What strategies can overcome challenges in generating stable lspA knockout strains in Y. pseudotuberculosis?

Generating stable lspA knockout strains in Y. pseudotuberculosis requires specialized strategies due to potential essentiality or growth defects. The conditional knockout approach using inducible promoters (arabinose-inducible PBAD or tetracycline-inducible systems) allows initial growth with lspA expression before inducer removal, facilitating isolation of complete knockouts if viable. Partial deletions targeting specific domains rather than the entire gene may preserve minimal function while disrupting specific activities. Merodiploid strains carrying a second functional lspA copy at a neutral chromosomal location under its native promoter allow deletion of the original gene for complementation studies. Transposon mutagenesis screening can identify suppressor mutations that permit growth of lspA-deficient strains, revealing genetic interactions. When conventional knockouts fail, CRISPR interference (CRISPRi) using catalytically inactive Cas9 provides tunable gene repression without complete deletion. For all approaches, use optimized growth conditions including reduced temperature (25°C instead of 37°C), rich media supplementation, and osmotic stabilizers (sucrose 5-10%) to support growth of membrane-compromised strains. Careful phenotypic characterization of resulting strains is essential, including growth rate measurement in various media, microscopic examination of cell morphology, and membrane integrity assays. Whole genome sequencing of successful knockouts identifies potential compensatory mutations. When studying essential genes, depletion approaches using protein degradation tags (e.g., SsrA tag) provide an alternative to complete deletion, allowing controlled reduction in protein levels .

How should researchers interpret conflicting data regarding lspA's role in virulence across different infection models?

Interpreting conflicting data on lspA's role in virulence across different infection models requires careful consideration of multiple experimental variables and biological contexts. Begin by systematically comparing key differences between the conflicting studies: bacterial strain backgrounds (serotype, virulence plasmid status), specific genetic constructions (deletion strategy, potential polar effects), infection models (animal species, infection route, inoculum dose), and readout parameters (colonization metrics, disease symptoms, survival endpoints). Host factors significantly influence outcomes – difference in results between mouse strains with varying immune profiles (C57BL/6 vs. BALB/c) may reflect genuine biological variability in host-pathogen interactions rather than experimental inconsistency. The infection route critically impacts virulence factor requirements; lspA may be essential for oral infection but dispensable for intraperitoneal challenge due to different barriers encountered. Temporal considerations are important – some virulence defects manifest only in specific infection phases (initial colonization, dissemination, or persistent infection). Complementation experiments are essential for resolving conflicting results, ideally using both plasmid-based and chromosomal restoration approaches to discriminate between direct and polar effects. When studies differ in methodology, direct side-by-side comparison experiments using standardized protocols across multiple infection parameters provide clarity. Collaborative cross-laboratory validation studies represent the gold standard for resolving persistent conflicts. Molecular mechanism investigations focusing on specific lspA-dependent processes in each model can reconcile apparent contradictions by revealing context-dependent functions .